Genmab — Capital/Financing Update 2013

Mar 13, 2013

Company Announcement

Copenhagen, Denmark; March 13, 2013
– Genmab A/S (OMX: GEN)
will increase its share capital by 405,000 shares as a consequence of the
exercise of employee warrants.

The
increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1: 25,000 shares at DKK 40.41,
95,000 shares at DKK 46.74, 25,000 shares at DKK 66.60, 2,250 shares at DKK
67.50 and 257,750 shares at DKK 86. Proceeds to the company are DKK 29,433,925.
The increase corresponds to approx. 0.81 % of the company's share
capital.

The
increase includes the exercise of 100,000 warrants by President & CEO Jan van
de Winkel. This will take Jan van de Winkel’s personal holding of shares in
Genmab A/S from 230,000 to 330,000 shares.

The new
shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2012. The new shares will be
listed on NASDAQ OMX Copenhagen after registration with the Danish Business
Authority. Genmab A/S' current share capital amounts to DKK 50,307,892 and will
after the capital increase be DKK 50,712,892. The capital increase is expected
to be finalized shortly.

About Genmab A/S
Genmab is a publicly traded, international
biotechnology company specializing in the creation and development of
differentiated human antibody therapeutics for the treatment of cancer.
Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®),
was approved to treat chronic lymphocytic leukemia in patients who are
refractory to fludarabine and alemtuzumab after less than eight years in
development. Genmab’s validated and next generation antibody technologies are
expected to provide a steady stream of future product candidates. Partnering
of innovative product candidates and technologies is a key focus of Genmab’s
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel
Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E:
r.gravesen@genmab.com

This Company Announcement contains
forward looking statements. The words “believe”, “expect”, “anticipate”,
“intend” and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially from any future
results or performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by
law.

Genmab A/S and its subsidiaries own the following
trademarks: Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody®, HexaBody(TM) and UniBody®. Arzerra® is a trademark of
GlaxoSmithKline.

Company Announcement no. 07
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark